202 filings
Page 2 of 11
8-K
IKT
Inhibikase Therapeutics, Inc.
30 Apr 24
Regulation FD Disclosure
8:17am
S-1/A
IKT
Inhibikase Therapeutics, Inc.
IPO registration (amended)
29 Apr 24
4:33pm
DEFA14A
IKT
Inhibikase Therapeutics, Inc.
26 Apr 24
Additional proxy soliciting materials
4:30pm
ARS
2023 FY
IKT
Inhibikase Therapeutics, Inc.
26 Apr 24
Annual report to shareholders
4:20pm
DEF 14A
IKT
Inhibikase Therapeutics, Inc.
Definitive proxy
26 Apr 24
4:15pm
S-1/A
IKT
Inhibikase Therapeutics, Inc.
IPO registration (amended)
25 Apr 24
4:29pm
S-1
IKT
Inhibikase Therapeutics, Inc.
IPO registration
19 Apr 24
5:14pm
8-K
IKT
Inhibikase Therapeutics, Inc.
18 Apr 24
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
9:46pm
PRE 14A
IKT
Inhibikase Therapeutics, Inc.
Preliminary proxy
15 Apr 24
4:09pm
4
Milton H. Werner
3 Apr 24
Inhibikase Therapeutics / Milton H. Werner ownership change
4:47pm
4
Garth Lees-Rolfe
2 Apr 24
Inhibikase Therapeutics / Garth Lees-Rolfe ownership change
5:14pm
3
Garth Lees-Rolfe
2 Apr 24
Inhibikase Therapeutics / Garth Lees-Rolfe ownership change
5:12pm
8-K/A
IKT
Inhibikase Therapeutics, Inc.
2 Apr 24
Departure of Directors or Certain Officers
5:12pm
10-K
2023 FY
IKT
Inhibikase Therapeutics, Inc.
Annual report
27 Mar 24
4:05pm
8-K
IKT
Inhibikase Therapeutics, Inc.
7 Feb 24
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA
7:59am
424B5
IKT
Inhibikase Therapeutics, Inc.
1 Feb 24
Prospectus supplement for primary offering
4:49pm
8-K
IKT
Inhibikase Therapeutics, Inc.
1 Feb 24
Entry into a Material Definitive Agreement
4:09pm
8-K
IKT
Inhibikase Therapeutics, Inc.
16 Jan 24
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
4:31pm
10-Q
2023 Q3
IKT
Inhibikase Therapeutics, Inc.
Quarterly report
14 Nov 23
4:15pm